Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer — Stella

Home/Efficacy and Safety/

View on ClinicalTrials.gov

Recruiting

Back to Efficacy and Safety trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Women's Hospital School Of Medicine Zhejiang University, Zhejiang, Hangzhou

Key details

Phase

Early testing / Safety & dosing

Sponsor

Xing Xie

Enrollment target

~50 participants

Started

July 2020

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Sex

Female only

Last updated December 2024